Lipid profile in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective lipid profile from single center

Simple item page
dc.contributor.authorÇalapkulu, Murat
dc.contributor.buuauthorCander, Soner
dc.contributor.buuauthorGül, Özen Öz
dc.contributor.buuauthorErsoy, Canan
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/Dahili Tıp Bilimleri/İç Hastalıkları Bölümü.tr_TR
dc.contributor.researcheridAAI-1005-2021tr_TR
dc.contributor.researcheridAAH-8861-2021tr_TR
dc.contributor.scopusid25027068600tr_TR
dc.contributor.scopusid26040787100tr_TR
dc.contributor.scopusid6701485882tr_TR
dc.date.accessioned2023-03-23T13:40:50Z
dc.date.available2023-03-23T13:40:50Z
dc.date.issued2019-01-17
dc.description.abstractIntroduction: Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor that improves glycemic control in patients with type II diabetes mellitus which increasing urinary glucose excretion. With numerous controlled experimental studies of dapagliflozin, evaluation of real-life data after entry into clinical practice is an important condition. In our study, the effects of dapagliflozin (10 mg) on lipid profile were investigated retrospectively. Methods: A total of thirty-one type 2 diabetic patients with HbA1c level between 6,5% and 13%, aged 45 -80 years and whose body mass index higher than 20 kg/m(2) were enrolled to the study. Data before dapagliflozin treatment and three and six months results were recorded. Results: Dapagliflozin reduced HbA1c levels by 0,9% at 3 months and 0,79% at 6 months. Total cholesterol level decreased 17,6 mg/dl, LDL cholesterol level decreased 13,4 mg/dl and triglyceride level by 25.9mg/dl at the 6th months and it is observed that there is no serious side effect on the usage for 6 months. Conclusion: There are conflicting results about the effect of SGLT2 inhibitors on the lipid profile in the literature. According to our data, dapagliflozin has positive effects on lipid profile as weight and glycemic control and it is well tolerated. Therefore, dapagliflozin therapy is beneficial because of the positive change in lipid profile and weight loss in diabetic patients with overweight and hyperlipidemia.en_US
dc.identifier.citationÇalapkulu, M. vd. (2019). ''Lipid profile in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective lipid profile from single center''. Diabetes & Metabolic Syndrome-Clinical Research & Reviews, 13(2), 1031-1034.en_US
dc.identifier.endpage1034tr_TR
dc.identifier.issn1871-4021
dc.identifier.issn1878-0334
dc.identifier.issue2tr_TR
dc.identifier.pubmed31336439tr_TR
dc.identifier.scopus2-s2.0-85060310525tr_TR
dc.identifier.startpage1031tr_TR
dc.identifier.urihttps://doi.org/10.1016/j.dsx.2019.01.016
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S1871402118306313
dc.identifier.urihttp://hdl.handle.net/11452/31723
dc.identifier.volume13tr_TR
dc.identifier.wos000466549300022tr_TR
dc.indexed.pubmedPubMeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosESCIen_US
dc.language.isoenen_US
dc.publisherElsevier Scienceen_US
dc.relation.journalDiabetes & Metabolic Syndrome-Clinical Research & Reviewsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectEndocrinology & metabolismen_US
dc.subjectType 2 diabetesen_US
dc.subjectDapagliflozinen_US
dc.subjectLipid profileen_US
dc.subjectLdlen_US
dc.subjectTotal cholesterolen_US
dc.subjectTriglycerideen_US
dc.subjectGlycemic controlen_US
dc.subjectTherapyen_US
dc.subject.emtreeCholesterolen_US
dc.subject.emtreeDapagliflozinen_US
dc.subject.emtreeHemoglobin A1cen_US
dc.subject.emtreeLow density lipoprotein cholesterolen_US
dc.subject.emtreeTriacylglycerolen_US
dc.subject.emtree2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triolen_US
dc.subject.emtreeVenzhydryl derivativeen_US
dc.subject.emtreeBiological markeren_US
dc.subject.emtreeGlucosideen_US
dc.subject.emtreeGlycosylated hemoglobinen_US
dc.subject.emtreeHemoglobin A1c protein, humanen_US
dc.subject.emtreeLipiden_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAgeden_US
dc.subject.emtreeBody massen_US
dc.subject.emtreeBody weight lossen_US
dc.subject.emtreeCholesterol blood levelen_US
dc.subject.emtreeClinical articleen_US
dc.subject.emtreeDiabetic patienten_US
dc.subject.emtreeDrug effecten_US
dc.subject.emtreeDrug tolerabilityen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeGlucose urine levelen_US
dc.subject.emtreeGlycemic controlen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeHyperlipidemiaen_US
dc.subject.emtreeLipid analysisen_US
dc.subject.emtreeLow density lipoprotein cholesterol levelen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeNon insulin dependent diabetes mellitusen_US
dc.subject.emtreeObesityen_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreeRetrospective studyen_US
dc.subject.emtreeReviewen_US
dc.subject.emtreeTriacylglycerol levelen_US
dc.subject.emtreeBlooden_US
dc.subject.emtreeClinical trialen_US
dc.subject.emtreeFollow upen_US
dc.subject.emtreeGlucose blood levelen_US
dc.subject.emtreeMiddle ageden_US
dc.subject.emtreeNon insulin dependent diabetes mellitusen_US
dc.subject.emtreePathologyen_US
dc.subject.emtreePrognosisen_US
dc.subject.emtreeVery elderlyen_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 and overen_US
dc.subject.meshBenzhydryl compoundsen_US
dc.subject.meshBiomarkersen_US
dc.subject.meshBlood glucoseen_US
dc.subject.meshDiabetes mellitus, type 2en_US
dc.subject.meshFemaleen_US
dc.subject.meshFollow-up studiesen_US
dc.subject.meshGlucosidesen_US
dc.subject.meshGlycated hemoglobin Aen_US
dc.subject.meshHumansen_US
dc.subject.meshLipidsen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPrognosisen_US
dc.subject.meshRetrospective studiesen_US
dc.subject.meshSodium-glucose transporter 2 inhibitorsen_US
dc.subject.scopusAntidiabetic Agent; Empagliflozin; Electron Microprobe Analysisen_US
dc.subject.wosEndocrinology & metabolismen_US
dc.titleLipid profile in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective lipid profile from single centeren_US
dc.typeReview

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
PubMed
Scopus